PT  - JOURNAL ARTICLE
AU  - Denkinger, C.M.
AU  - Janssen, M.
AU  - Schäkel, U.
AU  - Gall, J.
AU  - Leo, A.
AU  - Stelmach, P.
AU  - Weber, S. F.
AU  - Krisam, J.
AU  - Baumann, L.
AU  - Stermann, J.
AU  - Merle, U.
AU  - Weigand, M. A.
AU  - Nusshag, C.
AU  - Bullinger, L.
AU  - Schrezenmeier, J.F.
AU  - Bornhäuser, M.
AU  - Alakel, N.
AU  - Witzke, O.
AU  - Wolf, T.
AU  - Vehreschild, M. J.G.T.
AU  - Schmiedel, S.
AU  - Addo, M. M.
AU  - Herth, F.
AU  - Kreuter, M.
AU  - Tepasse, P.-R.
AU  - Hertenstein, B.
AU  - Hänel, M.
AU  - Morgner, A.
AU  - Kiehl, M.
AU  - Hopfer, O.
AU  - Wattad, M.-A.
AU  - Schimanski, C. C.
AU  - Celik, C.
AU  - Pohle, T.
AU  - Ruhe, M.
AU  - Kern, W. V.
AU  - Schmitt, A.
AU  - Lorenz, H.M.
AU  - Souto-Carneiro, M.
AU  - Gaeddert, M.
AU  - Halama, N.
AU  - Meuer, S.
AU  - Kräusslich, H.G.
AU  - Müller, B.
AU  - Schnitzler, P.
AU  - Parthé, S.
AU  - Bartenschlager, R.
AU  - Gronkowski, M.
AU  - Klemmer, J.
AU  - Schmitt, M.
AU  - Dreger, P.
AU  - Kriegsmann, K.
AU  - Schlenk, R. F.
AU  - Müller-Tidow, C.
TI  - Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trial
AID  - 10.1101/2022.10.10.22280850
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.10.10.22280850
4099  - http://medrxiv.org/content/early/2022/10/13/2022.10.10.22280850.short
4100  - http://medrxiv.org/content/early/2022/10/13/2022.10.10.22280850.full
AB  - Cancer patients are at high risk of severe COVID-19 with high morbidity and mortality. Further, impaired humoral response renders SARS-CoV-2 vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a multicenter trial (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE) in hospitalized patients with severe COVID-19 within four risk groups (1, cancer; 2, immunosuppression; 3, lab-based risk factors; 4, advanced age) randomized to standard of care (CONTROL) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (PLASMA). For the four groups combined, PLASMA did not improve clinically compared to CONTROL (HR 1.29; p=0.205). However, cancer patients experienced shortened median time to improvement (HR 2.50, p=0.003) and superior survival in PLASMA vs. CONTROL (HR 0.28; p=0.042). Neutralizing antibody activity increased in PLASMA but not in CONTROL cancer patients (p=0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcome in cancer patients unable to intrinsically generate an adequate immune response.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT Number 2020-001632-10Funding StatementThe trial was co-financed by the Federal Ministry of Education and Research, Germany (BMBF; emergency research funding RECOVER 01KI20152).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University of Heidelberg gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors